

**PATRICK SOON-SHIONG, M.D., MSc, FRCS(C), FACS.**

**CURRICULUM VITAE**

**EDUCATION**

M.B., B.Ch. (1975)

University of Witwatersrand  
Johannesburg, South Africa

M.Sc. (Surgery) (1979)

University of British Columbia  
Vancouver, British Columbia, Canada  
Thesis: Fundic Inhibition of Acid Secretion and Gastrin Release

F.R.C.S. (1983)

Fellow, Royal College of Surgeons (Canada)

Diplomate (1984)

American Board of Surgery  
Certification No: 29740

F.A.C.S. (1986)

Fellow, American College of Surgeons

**LICENSURE:**

State of California

**AFFILIATIONS**

Assistant Professor 1983 – 1989  
Gastro-Intestinal Surgery Division,  
Department of Surgery,  
Medical Center, UCLA  
Los Angeles, California

Associate Investigator 1984 - 1987  
Center for Ulcer Research & Education  
UCLA/VA Wadsworth Medical Center

Assistant Professor 1987 - 1989  
Department of Medicine  
UCLA

Director 1986 - 1989  
Pancreas Transplant Program  
UCLA  
Los Angeles, California

Visiting Scientist 1989  
Massachusetts Institute of Technology  
Boston, Massachusetts

Director, 1992 - 1998  
Islet Transplant Program  
National Institute of Transplantation

### **PROFESSIONAL ACTIVITIES**

United Network for Organ Sharing (UNOS) Region 5 Representative, National Pancreas Subcommittee to the Organ Procurement and Distribution Committee (1991 - 1993);  
Chairman, Pancreas and Islet Transplant Subcommittee, Region 5 (1991 - 1993);  
Chairman, Ad Hoc Pancreas and Islet Transplant Committee, Southern California Transplant Society (1991 - 1993)  
Human Studies Committee, Surgical Service Representative (1984 - 1988)  
Tissue Committee, Surgical Service Representative (1984 - 1988)  
Animal Research Committee, Surgical Service Representative (1985 - 1989)  
Policy Advisory Committee, Research Service (1986 - 1988)  
Asian/Pacific American Committee (1987 - 1989)  
Chairman, Pancreatic Transplantation Committee, Department of Surgery (1986 - 1989)  
Residency Review & Evaluation Committee, Department of Surgery (1986 - 1989)  
Executive Committee, Southern California Transplant Society (1986 - 1989)  
UCLA Surgery Resident's Program, Admissions Committee (1988 - 1989)

### **SOCIETY MEMBERSHIPS**

American Federation for Clinical Research (1983)  
Western Gut Club (1983)  
Earl J. Wolfman Surgical Society (1983)  
Association for Academic Surgery (1985)  
American Pancreatic Association (1985)  
Southern California Transplant Society (1985)  
American College of Surgeons (1986)  
Society for Surgery of the Alimentary Tract (1986)  
Mellinkoff Society, UCLA School of Medicine (1986)  
American College of Surgeons, Southern California Chapter (1986)  
American Diabetes Association (1986)  
Collegium Internationale Chirurgia Digestive (1986)  
American Association of Tissue Banks (1991)

### **UNDERGRADUATE HONORS AND AWARDS**

Merit Bar for Highest Class Aggregate (1965 - 1969)  
Wing King Memorial Prize (1968 - 1969)  
N.U.S.A.S. Scholar (1970 - 1971)  
Lo Ming Yuan Scholar (1970 - 1972)  
I.C.I. Award (1972 - 1975)  
CIBA-Geigy Award (1973)  
Rand Catholic Scholar (1973 - 1975)  
Noristan Laboratory Medal (1975)  
Noristan Laboratory Award (1975)

### **POSTGRADUATE HONORS AND AWARDS**

University of British Columbia First Prize Research by Surgical Resident (1978)  
University of British Columbia Third Prize Research by Surgical Resident (1979)  
British Columbia Surgical Society, Vancouver, First Prize Research (1979)  
Association for Academic Surgery Award for Research (1979)  
Royal College Physicians & Surgeons Canada Research Award (1980)  
Los Angeles Surgical Society Resident Research Presentation (1980)  
American College of Surgeons Schering Scholar (1981 - 1982)  
Sacramento Surgical Society First Prize Research by Surgical Resident (1982)  
NIH New Investigator Research Award (1983 - 1987)  
Membership Committee, Association of Academic Surgery (1987 - 1989)  
Chairperson, Islet Isolation in Large Animals & Man. 2nd International Congress on Pancreatic & Islet Transplantation, Minneapolis, Minnesota (1989)  
International J.W. Hyatt Award for Service to Mankind, Society of Plastics Engineer (1994)  
Eisenhower Medical Center, Peter Kiewit Distinguished Membership in Medicine (1994)  
NIH Invited Plenary Speaker: Vision for the Future Cell Therapy (1995)  
Keynote Speaker, Eighth International Symposium on Recent Advances in Drug Delivery Systems (1997)  
Keynote Speaker, American Institute for Medical and Biological Engineering (1998)  
Gilda's Club New York City, Award for the Advancement of Cancer Medicine (2006)  
Ellis Island Medal of Honor Award Recipient (2007)  
Caritas Gala Award Honoree (2007)  
USC Viterbi School of Engineering, Daniel J. Epstein Engineering Management Award (2008)

### **BOARD MEMBERSHIPS**

Board of Directors, China-Mary K. Iacocca Foundation (1988 - 1990)  
Board of Directors, Foundation for Transplant Research (1988 - Present)  
Scientific Advisory Board of Directors, National Institute of Transplantation (1990 - 1998)  
Research Advisory Board Member, PADRE (Pediatric and Adolescent Diabetes Research Foundation) (1991)  
Chairman, Board of Directors, American Bioscience Inc. (1994 - 2005)

Chairman, Board of Directors, American Pharmaceutical Partners (1996 - 2005)  
Member, Board of Trustees, The Buck Institute (2003-2006)  
Board of Trustees, National Institute of Transplantation (2004-Present)  
Chairman of the Board and Chief Executive Officer, Abraxis BioScience, Inc. (2005-Present)  
Board of Directors, Technology Council for the new Center for Cancer Nanotechnology Excellence at Northwestern University (part of the National Cancer Institute) (2006-present)  
Advisory Board, the RAND Corporation, RAND Center for Asia Pacific Policy (2006-present)  
Advisory Board, the RAND Corporation, RAND Health Board of Advisors (2006-present)  
Board Member, RAND – Center for Asia Pacific Policy Membership Committee (2007-present)  
Board of Trustees, Saint John’s Health Center (Jan.2007 – present)  
Board Member, California NanoSystems Institute (CNSI) Advisory & Oversight Board (2007-present)  
Advisory Board, UCLA, Henry Samueli School of Engineering & Applied Science – Institute for Technology Advancement (ITA) (2008-present)  
Board of Councilors, USC Viterbi School of Engineering (2008-present)  
Presidents Council, the RAND Corporation (Jan 2009-present)

**KEYNOTE SPEAKER:**

1. Milken Institute, CA State of the State Conference: California in the Year 2020, Panelist, Los Angeles, CA, - October 30, 2006.
2. Adaptive Business Leaders (ABL): “Paying for RX Miracles: Five Experts Speak Out- California 2020- Health Model of the Future”., San Francisco, CA, February 8, 2007.
3. University of California, System-Wide Technology Transfer Forum-Nanotechnology: “The Convergence of Biomedicine & Nanotechnology: Next Generation Medical Care”., San Francisco, CA, April 13, 2007.
4. Controlled Release Society (CRS) 34<sup>th</sup> Annual Meeting & Exposition, Plenary Speaker: “The Role of Biomarkers and Biologically Interactive Delivery Systems (receptor mediated transcytosis) in the Future of Chemotherapy”. Long Beach, CA, July 7-11, 2007.
5. Saint John’s Health Center – Post Graduate Assembly (PGA): “Vision for Translational Research”. Santa Monica, CA. Sept. 8, 2007.
6. (CNSI) California NanoSystems Institute / UCLA Nano-Bio Workshop: “The Role of Biomarkers and Biologically Interactive Delivery Systems (receptor mediated transcytosis) in the Future of Chemotherapy”. Los Angeles, CA. Sept.10, 2007.

7. NOVO Biosummit Meeting: "Perspectives on the Future of Health Care", Copenhagen, Denmark. Sept. 12, 2007.
8. (ABL) Adaptive Business Leaders: "Thinking Outside the Pill Box", Los Angeles, CA. Sept. 21, 2007.
9. Milken Institute: State of the State Conference: [Panelist]- "Is the Golden State Still a Leader in Global Innovation?", Los Angeles, CA, October 29, 2007.
10. (CNSI) California NanoSystems Institute / (CNBI) Center for NanoBio Integration: Symposium on NanoBiotechnology, Los Angeles, CA, November 1, 2007.
11. PODER Philanthropy Forum: "Strategic Philanthropy in the Health Arena, Addressing Root Causes, Not Symptoms", Miami, FL; March 12, 2008.

## **RESEARCH GRANTS AND FELLOWSHIPS RECEIVED**

1. NIH: National Institute of Arthritis, Diabetes & Digestive Diseases: "Inhibitory Mechanisms of the Gastric Fundus," AM-28297 Co-investigator, 1984-1986, \$377,000
2. NIH: National Institute of Arthritis, Diabetes & Digestive Diseases, New Investigator Research Award: "Non-Cholecystokinin Stimulant of Gallbladder Contraction," AM-34675, Principal Investigator, 1984-1987, \$107,000
3. Veterans Administration: Research Advisory Group: "Characterization of GI Secretagogues Acting on the Pancreas and Stomach," Principal Investigator, 1985, \$30,000
4. UCLA Departmental Grant Program: Salary for laboratory technician, 1/20-6/30/86, \$3,200
5. American Diabetes Association: "Monoclonal Antibody Purification and Microencapsulation in Pancreatic Islet Cell Transplantation," Principal Investigator, 1986-1988, \$50,000
6. UCLA Academic Senate Research Grant: "Development of an Artificial, Self-Regulating Pancreas in the Treatment of Diabetes," Principal Investigator, 7/1/86-6/30/87, \$2,000
7. Connaught Research Institute (Canada): "Microencapsulation Islet Cell Project," Principal Investigator, 2/22-5/23/87, \$40,000

8. American Diabetes Association, Designated "Islet Research" Award, Principal Investigator, 1987, \$50,000
9. American Diabetes Association: "Venous Thrombosis following Pancreas Transplant: Role of Oxy-Radical Damage and Leukocyte Adherence," Co-Investigator, 1987-1989, \$70,000
10. Iacocca Foundation: "Mary K. Iacocca Pancreas Transplant Fellow," Principal Investigator, 1987-1992, \$600,000
11. Pfeiffer Foundation: Clinical Islet Transplant Research, Principal Investigator, 1988-1991, \$90,000
12. Foundation for Transplant Research: Principal Investigator, "The Bioartificial Pancreas, and Nanoparticle feasibility Program" 1988-1991, \$100,000
13. VA Merit Review: "Islet Transplant Studies: Purification & Immunoisolation," Principal Investigator, 1989-1991, \$357,000
14. Foundation for Transplant Research: Principal Investigator, "Safety and Efficacy of Encapsulated Human Islets," 1992-1994, \$1,200,000
15. US Department of Commerce: Principle Investigator, "Human Islet Cell Proliferation, (Stem Cell Research Program)" 1996-1997, \$2,000,000

## LECTURES AND PRESENTATIONS

### Scientific Meetings

1. GIP: Its evaluation as an enterogastrone. Annual meeting of the American Association of Academic Surgery, Cleveland, Ohio, 1978
2. The insulinotropic and enterogastrone action of GIP under hyperlipemic and hyperglycemic states. Annual meeting of the Canadian Association of Gastroenterology, Montreal, Canada, 1979
3. Fundic inhibition of acid secretion and gastrin release. Annual meeting of British Columbia Surgical Society, Kamloops, B.C., (Prize Essay) 1979
4. Glucagon therapy in acute pancreatitis: A randomized, double-blind prospective study. Annual meeting of British Columbia Surgical Society, Kamloops, B.C. (with H.T. Debas, M.D.) 1979
5. Cholinergic inhibition of gastric inhibitory polypeptide action. Annual meeting of the American Gastroenterological Association, New Orleans, Louisiana, 1979
6. Fundic inhibition of acid secretion and gastrin release. Annual meeting of the American Gastroenterological Association, New Orleans, Louisiana, 1979
7. Pyloro-oxynitic neurohumoral inhibitory reflex of acid secretion. Annual meeting of the American Association of Academic Surgery, Great Gorge, New York, (Research Award) 1979
8. Definition of vagal pathways mediating inhibition and stimulation of gastrin release in the dog. Annual meeting of the American Gastroenterological Association, Salt Lake City, Utah, 1980
9. Fundic inhibition of acid secretion and gastrin release. Annual meeting of Royal College of Surgeons of Canada, Canadian Association of Gastroenterology, Ottawa, (Research Award) 1980
10. Fundic inhibitory mechanism: Pyloro-oxynitic inhibitory reflex and fundic inhibition of acid secretion. Annual meeting of the Royal College of Surgeons of Canada, Canadian Association of General Surgeons, Ottawa, 1980
11. Colonic inhibition of gastric acid secretion in man. Annual meeting of American College of Surgeons, Georgia, 1980
12. Vagal cholinergic inhibition of food-stimulated gastrin release in man. Annual meeting of American College of Surgeons, Georgia (with H.T. Debas, M.D.) 1980

13. Non-somatostatin, non-VIP fundic inhibition of acid secretion and gastrin release. Third International Symposium on Gastrointestinal Hormones, Cambridge, England, (with H.T. Debas, M.D.) 1980
14. Prevention by bethanechol of inhibition of gastric acid secretion by gastric inhibitory polypeptide (GIP). Third International Symposium on Gastrointestinal Hormones, Cambridge, England, (with H.T. Debas, M.D.) 1980
15. A fundic inhibitory mechanism. Annual meeting of Association of Academic Surgery, Birmingham, Alabama, 1980
16. Colonic inhibition of acid secretion in man. Annual meeting of Los Angeles Surgical Society, Los Angeles, California, 1980
17. Vagal distribution for stimulation and inhibition of gastrin release. Annual meeting of American Gastroenterological Association, New York, New York, (with H.T. Debas, M.D.) 1981
18. Vagal control of gastrin release: Pathways for stimulation and inhibition. Annual meeting of American College of Surgeons, San Francisco, California, (with H.T. Debas, M.D.) 1981
19. Clinical application of GI hormones in the preoperative localization of endocrine tumors. Annual meeting of the Sacramento Surgical Society, Sacramento, California, (Research Award) 1982
20. Increased serum induced gallbladder bioactivity in cholelithiasis due to non-CCK substance. Annual meeting of American Federation for Clinical Research, Carmel, California, 1983
21. The fundus as an inhibitory organ. Annual Medical Research Symposium, University of California, Davis, Sacramento, California, 1983
22. Non-CCK mechanism of gallbladder contraction in man. Semi-annual Research Symposium, Center for Ulcer Research & Education (CURE), Los Angeles, California, 1983
23. High recurrence rate of peptic ulcer disease following proximal gastric vagotomy: A hypothesis for its cause. Presented at University of the Witwatersrand, Department of Surgery Research Lecture, Johannesburg, South Africa, 1984
24. Non-CCK substance in human serum: Preliminary purification and mechanism of action. Semi-annual Research Symposium, Center for Ulcer Research & Education (CURE), Los Angeles, California, 1984

25. Epidermal growth factor (EGF): Interactions with CCK and secretin on exocrine pancreatic secretion. Annual meeting of American Gastroenterological Association, New Orleans, Louisiana (with H.T. Debas, M.D.) 1984
26. Non-CCK stimulant of gallbladder contraction in human serum: Chromatographic, immunologic and biologic comparisons to CCK. Annual meeting of American Gastroenterological Association, New Orleans, Louisiana, 1984
27. Non-CCK stimulant of gallbladder contraction in human serum: Comparisons between normal subjects and patients with gallstone disease. Annual meeting of Society for Surgery of the Alimentary Tract, New Orleans, Louisiana, 1984
28. Purification and mechanisms of action of non-CCK stimulant of gallbladder contraction. Surgeons Fourth Annual Symposium on Gut Hormones. Florissant, Colorado, The Nature Place (with H.T. Debas, M. D. ) 1984
29. Increased serum concentration of non-CCK stimulant of gallbladder contraction in patients with gallstone disease. Fifth International Symposium on Gastrointestinal Hormones, Rochester, Minnesota (with H.T. Debas, M.D.) 1984
30. Preliminary purification of a non-CCK stimulant of gallbladder contraction from porcine fundus. Fifth International Symposium on Gastrointestinal Hormones, Rochester, Minnesota (with H.T. Debas, M. D. ) 1984
31. Epidermal growth factor (EGF): In vivo interactions with CCK and secretin on exocrine pancreatic secretion. Fifth International Symposium on Gastrointestinal Hormones, Rochester, Minnesota (with H.T. Debas, M.D.) 1984
32. Immunogenicity and viability of a (-Class 11 immunotoxin-treated pig islet cells. XI International Congress of the Transplantation Society, Helsinki, Finland (with Y. Mullen, M.D.) 8/3 – 8/8/86
33. Adult acinar, but not islet, cells express blood group ABH antigens. Southern California Transplant Society, Los Angeles, California, 12/31/86
34. Pancreas Transplantation, Controversies in General and Vascular Surgery, Palm Springs, California, 3/10/87
35. An immunological method of pancreatic islet cell purification. XI Annual Meeting of Western Association of Transplant Surgeons, Los Angeles, California, 4/24/87
36. Multiple organ harvest and preservation: Pancreas. XI Annual Meeting of Western Association of Transplant Surgeons, Los Angeles, California, 4/24/87
37. Islet purification using anti-acinar monoclonal antibodies. International Organ Transplantation Forum, Pittsburgh, Pennsylvania, 9/8 – 9/11/87

38. Human acinar but not islet cells express blood group antigens: Use of this difference for islet cell purification using monoclonal antibodies. 21st Annual Meeting of the Association for Academic Surgery, Orlando, Florida, 11/1 – 11/4/87
39. Whole-organ pancreas transplantation in the rat with exocrine drainage into the urinary bladder. International Organ Transplantation Forum, Pittsburgh, Pennsylvania (with T. Zheng, M.D. and D.E.R. Sutherland, M.D.) 11/8 – 11/11/87
40. Pancreatic transplantation. Member Pancreatic Surgery Workshop Panel. Southern California Chapter, American College of Surgeons, Newport Beach, California, 1/23/88
41. What is the optimal use of monoclonal antibody today and in the future? Moderator. Frontiers in immunosuppression: New applications of monoclonal antibody therapy in organ transplantation, UCLA, Los Angeles, California, 2/5/88
42. New perspectives in diabetes treatment: Role of pancreas transplantation. UCLA 7th Annual Nora Eccles Harrison Symposium: Diabetes and Nutrition Update, Los Angeles, California, 3/26/88
43. Functional maturation of porcine fetal pancreatic explants. XII International Congress of the Transplantation Society, Sydney, Australia, 8/4 – 8/19/88
44. Elevation in urinary prostaglandin (PGE<sub>2</sub>) as an early marker of pancreas allograft rejection. XII International Congress of the Transplantation Society, Sydney, Australia, 8/14 – 8/19/88
45. Identification of novel blood group-reactive monoclonal antibodies cytotoxic to human acinar cells but not islets. XII International Congress of the Transplantation Society, Sydney, Australia, 8/14 – 8/19/88
46. Urinary prostaglandin (PGE<sub>2</sub>) as an early marker of pancreas allograft rejection. Eighth Workshop Pancreas and Islet Transplantation, European Association for the Study of Diabetes, Igls, Austria, 1/29 – 1/31/89
47. Use of monoclonal antibodies in islet purification. Eighth Workshop Pancreas and Islet Transplantation, European Association for the Study of Diabetes, Igls, Austria, 1/29 – 1/31/89
48. Promising solutions to the obstacles facing islet transplantation in man. 13th Annual Western Association of Transplant Surgeons, Salt Lake City, Utah, 3/10/89
49. Rapid purification of islets using magnetic microspheres coated with anti-acinar cell monoclonal antibodies. 15th Annual Scientific Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, 5/31 - 6/2/89

50. Islet purification by a novel immunomicrosphere cell depletion technique. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, 9/21 – 9/22/89
51. Acinar cell depletion by anti-acinar conjugated magnetic microspheres. 2nd Workshop on Methods in Islet Transplantation Research, Giessen, West Germany, 6/22 – 6/24/89
52. Microencapsulation: New biocompatible materials: An in vitro method for evaluating immunoprotective efficacy of new biomaterials. 2nd Workshop on Methods in Islet Transplantation Research, Giessen, West Germany, 6/22 – 6/24/89
53. An in vitro method of assessing the immunoprotective properties of microcapsule membranes using pancreatic and tumor cell targets. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, 9/21 – 9/22/89
54. PGE2 elevation occurs in the urine in both bladder and duodenally-drained pancreas allograft rejection. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, 9/21 – 9/22/89
55. Urinary insulin as a marker of rejection in the bladder-drained pancreas allograft. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, 9/21 – 9/22/89
56. Invited speaker at workshop: Standards for islet evaluation. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, 9/21 - 22/89
57. Invited speaker on ten member panel: Biohybrid artificial pancreas workshop. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, 9/20 – 9/22/89
58. Chairperson: Islet isolation in large animals and man. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, 9/21 – 9/22/89
59. Successful long term transplantation of a bioartificial pancreas in the large and small animal model. Annual Meeting Western Association of Transplant Surgeons, Oakland, California, 3/9/90
60. Improved pancreas preservation using a new cardioplegic solution containing polyethylene glycol (Cardiosol). 16th Annual Scientific Meeting American Society of Transplant Surgeons, Chicago, Illinois, 5/30 - 6/1/90
61. An immunoprotected insulin secreting organ for transplantation. Fifth Annual Symposium Biotechnology Process Engineering Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, 6/18 – 6/20/90

62. An immunological basis for the fibrotic reaction to implanted microcapsules. XIII International Congress of the Transplantation Society, San Francisco, California, 8/19 – 8/24/90
63. Microcapsule technology in islet transplantation. Carousel of Hope Symposium: New Frontiers in the detection and treatment of Type I diabetes, Los Angeles, 10/3/90
64. Successful long term reversal of Type I diabetes by microencapsulated islet transplantation. Western Association of Transplant Surgeons. 1991 Western Association of Transplant Surgeons Annual Meeting, Newport Beach, California, 3/9/91
65. Overcoming alginate-based microcapsule fibrosis: proof of principle studies in spontaneous diabetic dogs. American Society for Artificial Internal Organs. 37th Annual Meeting and Exposition, Chicago, Illinois, 4/26/91
66. Successful long-term reversal of spontaneous diabetes following bioartificial pancreas transplantation. American Society of Transplant Surgeons. 17th Annual Scientific Meeting of the ASTS, Chicago, Illinois, 5/29 – 5/31/91
67. Plenary Session: Long-term euglycemia in spontaneous diabetic dogs by microencapsulated islet transplantation. 3rd International Congress on Pancreatic and Islet Transplantation Symposium on Artificial Insulin Delivery System, Lyon, France, 6/6 – 6/8/91
68. Glucose-insulin kinetics of the extravascular bioartificial pancreas in the small and large animal model. 3rd International Congress on Pancreatic and Islet Transplantation Symposium on Artificial Insulin Delivery System, Lyon, France, 6/6 – 6/8/91
69. A physiological islet purification solution (PIPS). 3rd International Congress on Pancreatic and Islet Transplantation Symposium on Artificial Insulin Delivery System, Lyon, France, 6/6 – 6/8/91
70. Overcoming underlying mechanisms of microcapsule fibrosis. 3rd International Congress on Pancreatic and Islet Transplantation Symposium on Artificial Insulin Delivery System, Lyon, France, 6/6 – 6/8/91
71. Successful reversal of hyperglycemia by one-to-one rat islet transplant using a two-phase aqueous purification solution. 3rd International Congress on Pancreatic and Islet Transplantation Symposium on Artificial Insulin Delivery System, Lyon, France, 6/16 – 6/18/91
72. Successful reversal of Type I diabetes by a bioartificial pancreas. 14th International Diabetes Federation Congress, Washington, D.C., 6/23 – 6/28/91

73. Biocompatible alginate based microcapsules in spontaneous diabetic dogs. VIII World Congress of the International Society for Artificial Organs, Montreal, Canada, 8/19 – 6/22/91
74. Prolongation of canine and human islet xenograft in STZ-induced diabetic rats by microencapsulation. 1st International Congress on Xenotransplantation, Minneapolis, Minnesota, 8/25 – 6/28/91
75. Biocompatible immunoprotective systems for xenotransplantation. 1st International Congress on Xenotransplantation, Minneapolis, Minnesota, 8/25 – 6/28/91
76. Structure - Function correlation of alginate - Polycation capsules relevant to their use as a bioartificial pancreas. First International Congress of the Cell Transplant Society, Pittsburgh, Pennsylvania, 5/31 - 6/3/92
77. Successful retransplantation of microencapsulated islets in spontaneous diabetic dogs: Long-term follow up. First International Congress of the Cell Transplant Society, Pittsburgh, Pennsylvania, 5/31 - 6/3/92
78. Human C-Peptide response in xenotransplanted diabetic Lewis rats. First International Congress of the Cell Transplant Society, Pittsburgh, Pennsylvania, 5/31 - 6/3/92
79. Successful long-term reversal of diabetes by a bioartificial pancreas. National University of Singapore, Society of Chinese Bioscientists in America, Fourth International Symposium and Workshop, Singapore, 6/14 – 6/19/92
80. "Fluorinated Hydrocarbons as MRI Contrast Agents", with M. W. Grinstaff, K. J. Kolbeck, R. L. Magin, K. S. Suslick, L. J. Wilmes, and M. Wong, IEEE Engineering in Medicine and Biology Society Meeting, San Diego, CA, 1993.
81. "Intravenous Targeted Delivery of Taxol in Protein Microspheres", with M. W. Grinstaff, R. L. Magin, K. S. Suslick, M. Wong, P. A. Sandford, and P. Soon-Shiong, ACS Spring Meeting, San Diego, California, March 1994.
82. "In vitro and In vivo Function of Islets of Langerhans Encapsulated in Novel Photocrosslinkable Alginates", ACS Spring Meeting, San Diego, California, March 1994.
83. "Controlled and Targeted Drug Delivery with Biocompatible Protein Shell Microspheres", 20th annual meeting of the Society For Biomaterials, Boston, Massachusetts, April 1994.
84. "Fluorocarbon Filled Protein Microspheres as Contrast Agents for Magnetic Resonance Imaging", with M. W. Grinstaff, K. J. Kolbeck, R. L. Magin, K. S. Suslick, A. Webb, L. J. Wilmes, M. Wong, P. A. Sandford, and P. Soon-Shiong, 20th annual meeting of the Society For Biomaterials, Boston, Massachusetts, April 1994.

85. "Immunoisolation of Xenografted Islets in Dually (Ionic and Covalent) Crosslinked Alginate Hydrogels", 20th annual meeting of the Society For Biomaterials, Boston, Massachusetts, April 1994.
86. In vitro and in vivo Function of islets of Langerhans encapsulated in novel photocrosslinkable alginates. 207th American Chemical Society National Meeting, San Diego, California, 3/13 – 3/17/94
87. First human trial with encapsulated human islets in a type I diabetic patient - normoglycemia with sustained Islet Function 6 months post encapsulation. 207th American Chemical Society National Meeting, San Diego, California, 3/13 – 3/17/94
88. Normoglycemia with sustained islet function in a type I diabetic patient 6 months post encapsulated islet transplant. Cell Transplant Society, Minneapolis, Minnesota, 4/1 – 4/4/94
89. Long-term euglycemia in diabetic mice following intraperitoneal transplantation of highly discordant encapsulated canine islet xenografts without immunosuppression. Cell Transplant Society, Minneapolis, Minnesota, 4/1 – 4/4/94
90. Current issues in blood substitute research and development. University of California, San Diego Postgraduate Course, 3/30 - 4/1/95
91. "In vivo Drug Delivery with Biocompatible Protein Shell Microspheres", 21st annual meeting of the Society For Biomaterials, San Francisco, CA, March 1995.
92. "Protein Microcapsules as Drug Delivery Vehicles", Conference on Pharmaceutical Science and Technology, Chicago, Illinois, USA, August 1995.
93. Xenograft transplantation: science, ethics, and public policy. National Academy of Sciences IOM Workshop, 6/25 – 6/27/95
94. Neonatal porcine islets - in vivo and in vitro. Islet Cell Study Group Meeting, Hannover, Germany, Sept. 1996
95. "Protein-Stabilized Nanoparticles as Drug Delivery Vehicles", 23rd annual meeting of the Society For Biomaterials, New Orleans, Louisiana, April 1997.
96. Next generation biological delivery systems in clinical development. University of Utah, Controlled Chemical Delivery Eighth International Symposium on Recent Advances in Drug Delivery Systems, Feb. 1997
97. Biochemistry and biotechnology of industrial polysaccharides. American Chemical Society, 4/15/97

98. Bioartificial pancreas. ASAIO, Atlanta, Georgia, May 1997
99. Protein-stabilized nanoparticles as drug delivery systems. 23<sup>rd</sup> Annual Meeting of the Society For Biomaterials, 5/3/97
100. Phase I study of cremophor-free, protein-stabilized , nanoparticle formulation of paclitaxel (ABI-007) in solid tumors. Thirty-sixth Annual Meeting, American Society of Clinical Oncology, May, 2000, New Orleans, LA, USA.
101. A novel intra-arterial chemotherapeutic approach to squamous cell cancer of head and neck and anal canal using high dose cremophore-free paclitaxel/albumin nanoparticles (ABI-007). Thirty-sixth Annual Meeting, American Society of Clinical Oncology, May, 2000, New Orleans, LA, USA.
93. Protein-based nanoparticles for drug delivery of paclitaxel. Sixth World Biomaterials Congress, May, 2000, Kamuela, Hawaii, USA.
102. Desai NP, Yao Z., Soon-Shiong P: Evidence of Enhanced In Vivo Efficacy at Maximum Tolerated Dose (MTD) of Nanoparticle Paclitaxel (ABI-007) versus Taxol in 5 Human Tumor Xenografts of Varying Sensitivity to Paclitaxel. May 18-21, 2002, Orlando, Florida, USA.
94. Ibrahim NK, Samuels B., Page R., Guthrie T., Ramakrishnan G., Doval D., Patel K., Rao S., Nair M., Digumarti R., Hortabagyi GN.: Nanoparticle Paclitaxel (ABI-007) in Metastatic Breast Cancer (MBC): Efficacy and Evidence of Dose-dependent Activity in Two Multicenter Phase II Studies. May 18-21, 2002, Orlando, Florida, USA.
95. Campbell KJ., Hersh EM., Stopeck AT., Glennie K., Simpson GA., Taylor C., Von Hoff DD.: A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-hematologic Malignancies. May 18-21, 2002, Orlando, Florida, USA.
96. Ibrahim NK., Samuels B., Page R., Guthrie T. Jr., Doval D., Patel KM., Rao SC., Nair M., Digumarti R., Hortobayi GN.: Efficacy and Dose-Dependent Activity of ABI-007, a Cremophor®-Free Nanoparticle Paclitaxel, in First-Line Metastatic Breast Cancer: Integrated Results of Two Phase II Trials. December 11-14, 2002, San Antonio, Texas, USA.
97. Taylor C., Ibrahim NK., Page R., Guthrie T. Jr., Rao SC., Digumarti R., Desai N., Soon-Shiong P.: Preliminary Evidence of Antitumor Activity of ABI-007, a Cremophor®-Free Nanoparticle Paclitaxel, in Patients Previously Exposed to Taxanes. December 11-14, 2002, San Antonio, Texas, USA.
98. Desai N., Campbell K., Ellerhorst J., Ibrahim NK., Soon-Shiong P.: Preclinical

and Clinical Pharmacokinetics and Safety of ABI-007-a Novel, Cremophor®-Free, Protein-Engineered Nanotransporter of Paclitaxel. December 11-14, 2002, San Antonio, Texas, USA.

99. Desai N., Yao Z., Trieu V., Soon-Shiong P., Dykes D., Noker P.: Evidence of a Novel Transporter Mechanism for a Cremophor®-Free, Protein-Engineered Paclitaxel (ABI-007) and Enhanced In Vivo Antitumor Activity in an MX-1 Human Breast Tumor Xenograft Model. December 11-14, 2002, San Antonio, Texas, USA.

### **Invited Speaker**

1. Update on pancreas transplants. City of Hope National Medical Center Duarte, California, Nov.1985
2. Pancreatic transplants in diabetes. UCLA Board of Visitors, 3/25/86
3. Pancreatic transplantation in diabetes. UCLA Perioperative Nursing Staff, 5/7/86
4. Pancreatic transplantation in treatment of diabetes. UCLA Surgical Grand Rounds, 9/24/86
5. Current status of pancreas transplantation. Cedars-Sinai Surgical Grand Rounds, 9/24/86
6. Pancreatic transplantation. University of Southern California Surgical Grand Rounds, 9/26/86
7. Pancreas transplantation for the treatment of diabetes. UC Irvine, Diabetes Research Team, 10/28/86
8. Pancreas transplantation. Association of Operating Room Nurses, 11/1/86
9. Pancreas transplantation for the treatment of diabetes mellitus. American Diabetes Association, Southern California Affiliate Key Note Speaker, 11/9/86
10. Pancreatic transplantation. Blue Cross of California Statewide Medical Policy Meeting, 12/10/86
11. Case report: first pancreas transplant at UCLA. UCLA Nephrology Rounds, 11/13/86
12. Pancreas transplant program at UCLA. UCLA Anesthesiology Grand Rounds, 12/3/86
13. Pancreas transplantation in diabetes: current status and future prospects. UCLA Medical Grand Rounds, 12/17/86
14. Current status of pancreas transplantation. Kaiser Permanente (Panorama City) Surgical Grand Rounds, 2/11/87
15. Advances in diabetes treatment: the role of pancreas transplantation. American Diabetes Association, San Fernando Valley Chapter, 3/5/87
16. Transplants: the hope and the hurdles whole-organ pancreas transplants. American Diabetes Association, Orange County Chapter, 3/7/87

17. Surgical emergencies for the internist. Internal Medicine Noon Conference, UCLA, 3/31/87
18. Pancreatic transplants for the control of diabetes. American Diabetes Association, South Bay Chapter, 4/16/87
19. Future prospects for islet cell transplantation. VA Wadsworth Medical Center, Division of Endocrinology, Research Service, 4/16/87
20. Current status of pancreas transplantation. St. Joseph's Hospital, Organ Tissue Awareness Symposium, 5/1/87
21. Surgical approach to the acute abdomen. UCLA Emergency Medicine Grand Rounds, 5/19/87
22. Current status of pancreas transplantation. UCLA Harbor Medical Center Surgical Grand Rounds, 5/30/87
23. Whole-organ and islet cell pancreatic transplantation. Mission Community Hospital, Mission Viejo, California 6/9/87
24. Vital organ donation and pancreatic transplantation. Medical Center of North Hollywood, 6/24/87
25. Pancreatic transplantation. Holy Cross Hospital, Mission Hills, California, 6/30/87
26. Surgical approach to the acute abdomen. UCLA Family Practice Grand Rounds, 8/8/87
27. Whole-organ and islet cell pancreas transplantation. Inland Society of Internal Medicine, San Bernardino, California, 10/27/87
28. New perspectives in diabetes care: the role of pancreas transplantation. Los Angeles Chapter, California Affiliate of the American Diabetes Association, Professional Section Meeting, Los Angeles, California, 11/5/87
29. Pancreas transplantation program at UCLA. Third Annual Meeting of the Southern California Transplant Society, Los Angeles, California, 12/9/87
30. Pancreatic transplantation. Diabetes Grand Rounds, Department of Internal Medicine, USC Medical Center, Los Angeles, California, 1/15/88
31. Pancreas transplantation. Pediatric Endocrinology Grand Rounds, City of Hope National Center, Duarte, California, 1/27/88

32. Future trends in diabetes. Third Annual Pump & Intensive Insulin Therapy Seminar, American Diabetes Association, Panel Member, Long Beach, California, 3/19/88
33. Diabetes mellitus. Return to Basic Sciences, course #ME-116, UCLA Medical Center, 4/5/88
34. Chairman's Rounds, UCLA Department of Surgery, 4/13/88
35. Pancreatic transplantation. St. Mary Medical Hospital Noon Conference, National Organ and Tissue Donor Awareness Week, Long Beach, California, 4/25/89
36. Pancreas transplantation. UCLA Harbor Medical Center Endocrine Clinical Conference, Department of Internal Medicine, 4/26/89
37. Advances in diabetes treatment. American Diabetes Association, San Fernando Valley Chapter, Tarzana, California, 5/4/89
38. Pancreatic transplantation. Torrance Memorial Hospital Medical Education Conference, Torrance, California, 6/7/89
39. Current status of pancreatic transplantation for diabetes. USC Grand Rounds, Division of Endocrinology, Department of Internal Medicine, LAC General Hospital, Los Angeles, California, 7/7/89
40. State of the art of pancreas and islet transplantation. Century City Hospital Medical Education Seminar, Los Angeles, California, 7/15/89
41. Islet cell transplantation. UCLA Symposium on Solid Organ Transplantation, Los Angeles, California, 9/23/89
42. Current status of pancreas transplantation. UCLA Surgical Grand Rounds, 10/25/89
43. Pancreatic transplantation. Interstate Postgraduate Medical Association of North America, San Diego, California, 11/7/89
44. Islet cell pancreatic transplantation: the future for our diabetic patients. Challenges in Renal Transplantation, USC School of Medicine Postgraduate Medical Education and St. Vincent Medical Center, Los Angeles, California, 2/23-2/24/90
45. Islet transplantation without immunosuppression a clinical reality? Endocrinology, Department of Medicine, VA Wadsworth Medical Center, Los Angeles, California, 3/22/90
46. The role of islet transplantation in the treatment of type I diabetes. Department of Medicine Grand Rounds, VA Wadsworth Medical Center, Los Angeles, California, 5/2/90

47. Islet cell transplantation for the treatment of type I diabetes mellitus. Noon Lecture, The Hospital of the Good Samaritan, Los Angeles, California, 5/3/90
48. Pancreas and islet cell transplantation. USC Grand Rounds, Division of Diabetes, Hypertension & Nutrition, LAC General Hospital, Los Angeles, California, 8/31/90
49. Progress in islet transplantation using encapsulated islets. Mayo Clinic, Rochester, Minnesota, 9/18/90
50. Update on diabetes The Hospital of the Good Samaritan, Los Angeles, California, Oct.1990
51. Islet cell transplantation. American Diabetes Association, Orange County Chapter, Orange, California, 2/9/91
52. Islet transplantation. VIII World Congress of the International Society for Artificial Organs, Montreal, Canada, 8/19/91
53. Keynote Speaker: Current status of islet transplantation. Speaker: Microencapsulated islets: the future. LDS Hospital, Medicine in the Intermountain West Conference, Salt Lake City, Utah, 5/3-5/4/91
54. Microencapsulated islet cell transplantation. Children's Hospital of Orange County, Recent Advances in Diabetes Seminar, Orange, California, 9/21/91
55. Status of islet cell transplantation in the diabetic patient. Sharp Memorial Hospital Continuing Medical Education, Renal Transplantation in the 1990's, Newport Beach, California, 2/29/92
56. Encapsulated islet transplantation update. Sansum Medical Research Center, Santa Barbara, 6/8/92
57. University of Minnesota, Department of Surgery, Transplant Conference, 7/30/92
58. Islet cell transplantation - a potential cure for diabetes. Eisenhower Medical Center, Rancho Mirage, California, 1/13/93
59. Long-term reversal of diabetes by injection of immunoprotected islet cells. American Diabetes Association Symposium, 3/13/93
60. Islet cell transplantation. Oregon Health and Science University, 4/15/93
61. Organ donation consideration for the primary care physician. Long Beach Medical Center, 7/16/93
62. Islet cell transplantation. Little Company of Mary Hospital, 7/21/93

63. Islet cell transplant. Northridge Hospital, 11/11/93
64. Encapsulated islet cell transplantation. Eisenhower Medical Center, 1/14/94
65. Encapsulated islet cell transplantation. International Transplant Nurses Society, San Francisco, 2/17/94
66. Pancreatic islet cell transplantation. American College of Physicians Regional Meeting, 2/25/94
67. Microencapsulation of islets. National Institute of Diabetes & Digestive Kidney Disease, 4/5/94
68. Transplantation: Diabetes Treatment in the 20th Century. Annenberg Center, 4/6/95
69. Microencapsulation of islets. National Institute of Health Workshop, 4/7/94
70. Immunoisolation of xenografted islets in dually (ionic & covalent) crosslinked alginate hydrogels. Seventh International Symposium on Recent Advances in Drug Delivery Systems, 3/2/95
71. Alginate encapsulation: update on first human clinical trial with encapsulated human islets in a type I diabetic patient with sustained islet function 16 months post encapsulated islet transplant. American Chemical Society National Meeting, 4/4/95
72. Clinical studies using microencapsulated islets. Keystone Symposia on Molecular and Cellular Biology, 4/5/95
73. Microencapsulated cell therapy for diabetes mellitus. The Ninth International Biotechnology Meeting & Exhibition, 5/25/95
74. Cell encapsulation: transplantation & therapy. American Society for Artificial Internal Organs Conference, 5/5/95
75. Biomaterials and medical implant science: present and future perspectives. National Institute of Health Workshop, 10/17/95
76. NASA: The Investigators Working Group (IWG), Houston, Texas, 2/23/96
77. Day of hope. Desert Diabetes Club of the Eisenhower Medical Center, Annenberg Center, 3/30/96
78. BioCentury: Future Leaders in the Biotech Industry - 4/11/96
79. Clinical edge: emerging treatment modalities. Premier Annual Stockholders Meeting CEO Conference, 10/9/96

80. Next generation biological delivery systems in clinical development, Keynote Speaker. 8<sup>th</sup> International Symposium on Recent Advances in Drug Delivery Systems, 2/26/97
81. Clinical studies update. Premier, Medical Leadership Forum, Apr.1997
82. A vision of the future: medicine for the new millennium. Pacific International Medical Congress 2000, Victoria, B.C., 6/29/00
83. Delivery of biologics in the new millennium. Chicagoland Pharmaceutical Discussion Group Symposium, Chicago 3/2/01
84. Bank of America Securities Healthcare Conference, Las Vegas, 4/2/02.
85. CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference, New York, 5/1/2002.
86. UBS Warburg, Global Specialty Pharmaceuticals Conference, New York, 6/5/02.
87. UBS Warburg, Global Life Sciences Conference, New York, 10/7/02.
88. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference, New York, 2/5/03.
89. Bank of America Securities Healthcare Conference, Las Vegas, 3/25/03.
90. CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference, 04/30/03.

## BIBLIOGRAPHY

### Publications

1. Soon-Shiong P, Debas HT, Brown JC: Evaluation of GIP as the enterogastrone. *J Surg Res* 26:681-686, 1979
2. Soon-Shiong P: Fundic Inhibition of Acid Secretion and Gastrin Release. M.Sc. (Surgery) thesis
3. Soon-Shiong P, Debas HT: Pyloro-oxyntic neurohumoral inhibitory reflex of acid secretion. *J Surg Res* 28:198-203, 1980
4. Soon-Shiong P, Debas HT: Fundic inhibition of acid secretion and gastrin release. *Gastroenterology* 79:867-872, 1980
5. Soon-Shiong P, Seal AM, Debas HT, Walsh JH, Cheung G: Colonic inhibition of gastric acid secretion in man. *Surg Forum* 31:152-154, 1980
6. Debas HT, Soon-Shiong P, Walsh JH, Cheung G: Vagal cholinergic inhibition of food-stimulated gastrin release in man. *Surg Forum* 31:167-169, 1980
7. Debas HT, Hancock RJ, Soon-Shiong P, Smythe HA, Cassium MM: Glucagon therapy in acute pancreatitis: A prospective randomized double-blind study. *Can J Surg* 23:578-580, 1980
8. Debas HT, Chaun H, Thomson FB, Soon-Shiong P: Functioning heterotopic oxyntic mucosa in the rectum: A case report. *Gastroenterology* 79:1300-1302, 1980
9. Soon-Shiong P, Bock L, Debas HT: A non-vasoactive intestinal polypeptide, non-somatostatin fundic inhibitory mechanism. *J Surg Res* 30(5):473-477, 1981
10. Soon-Shiong P, Debas HT: Prevention of infection in gastroduodenal and biliary surgery: Intraabdominal infections. McGraw-Hill, New York, pp. 256-266, 1981
11. Debas HT, Seal AM, Cork C, Soon-Shiong P, Walsh JH: Vagal distribution for stimulation and inhibition of gastrin release. *Surg Forum* 32:143-145, 1981
12. Debas HT, Soon-Shiong P, McKenzie AD, Bogoch A, Dunn L: The use of secretin in the roentgenologic and biochemical diagnosis of duodenal gastrinoma. *Am J Surg* 145(3):408-411, 1983
13. Soon-Shiong P, Debas HT, Brown JC: Bethanechol prevents inhibition of gastric acid secretion by gastric inhibitory polypeptide. *Am J Physiol* 247(2Pt 1):G171-5, 1984

14. Debas HT, Hollinshead J, Seal AM, Soon-Shiong P, Walsh JH: Vagal control of gastrin release in the dog: Pathways for stimulation and inhibition. *Surgery* 95(1): 34-7, 1984
15. Soon-Shiong P, Cox KJ, Rosenquist GL, Iwashii-Hosoda C, Carr H: Increased concentration of a noncholecystokinin stimulant of gallbladder contraction in patients with gallstone disease. *Surg Forum* 35:194-6, 1984
16. Soon-Shiong P, Cox KL, Rosenquist GL, Iwashii-Hosoda C: Evidence for a non-cholecystokinin stimulant of gallbladder contraction: Comparison of fasting serum concentration in normal subjects and in patients with gallstones. *Am J Surg* 149(1): 163-6, 1985
17. Mantyh CR, Brecha NC, Soon-Shiong P, Mantyh PW: Specific binding sites for atrial natriuretic factor in the human kidney. *N Engl J. Med* 312(26): 1710, 1985
18. Soon-Shiong P, Swafford G, Levin S: Successful long-term exocrine and endocrine function in the autotransplanted pancreas in man. *Pancreas* 2(3): 357-61, 1987
19. Soon-Shiong P, White G: New advances in pancreatic transplantation. *West J Med* 146:734, 1987 (Invited article.)
20. Soon-Shiong P: Diabetes: New Cures in the Offing? *UCLA Health Insights*, December, 1987
21. Soon-Shiong P, Heintz R, Terasaki P: An immunological method of islet cell purification using cytotoxic anti-acinar cell monoclonal antibodies. *Transplant Proc* 20 (suppl 1):61-63, 1988
22. Soon-Shiong P, Heintz R, Terasaki P: Characterization of monoclonal antibodies CBL3 and TT62 with differing antigenic determinants specific for isolated human islet cells. *Biochem Biophys Res Comm* 150(2): 775-80, 1988
23. Soon-Shiong P, Grewal IS: Enhancement of lectin-induced cap formation in human neutrophils by Cyclosporin A. *Biochem Biophys Res Comm* 151(1): 435-40, 1988
24. Bredenkamp J, Korzelius J, Mann B, Soon-Shiong P: Extrahepatic biliary thrombus as the only presentation of hepatocellular carcinoma. *Contemp Surg*, 1988
25. Soon-Shiong P, White G, DeMayo E, Koyle M, Danovitch G: Mechanical obstruction of the portal vein as a cause of vascular thrombosis after pancreatic transplantation in man. *Transplant Proc* 20(5): 1059-61, 1988
26. Ginier P, Levin SR, Swafford G, Soon-Shiong P: Absence of the "incretin" phenomenon in the autotransplanted human pancreas. *Pancreas* 3(6): 740-1, 1988

27. Tsunoda T, Furui H, Klandorf H, Soon-Shiong P, Mullen Y: Functional maturation of porcine fetal pancreatic explants. *Transplant Proc* 21(1 pt 3): 2667-8, 1989
28. Soon-Shiong P, Zheng T, Merideth N, Chang Y: Elevation in urinary prostaglandin (PGE<sub>2</sub>) as an early marker of pancreas allograft rejection. *Transplant Proc* 21(1 Pt 3): 2771-3, 1989
29. Soon-Shiong P, Heintz R, Terasaki P: Identification of novel blood group-reactive monoclonal antibodies cytotoxic to human acinar cells but not islets. *Transplant Proc* 21(1 Pt 3): 2622-3, 1989
30. Soon-Shiong P, Lu ZN, Grewal 1, Lanza RP, Clark WR: Prevention of CTL and NK cell-mediated cytotoxicity by microencapsulation. *Horm Metab Res Suppl* 25: 215-9, 1990
31. Soon-Shiong P, Heintz R, Fujioka T, Terasaki P, Merideth N, Lanza RP: Utilization of anti-acinar cell monoclonal antibodies in the purification of rat and canine islets. *Horm Metab Res Suppl* 25: 45-50, 1990
32. Parker L, Lifrak E, Shively J, Soon-Shiong P: Control of adrenal androgen secretion. In: *Proceedings of the Eighteenth Steenbock Symposium: Hormones, thermogenesis and obesity*. Hardy HA (Ed). Elsevier Press, New York, 1989
33. Fujioka T, Terasaki P, Heintz R, Merideth N, Lanza RP, Zheng TL, Soon-Shiong P: Rapid purification of islets using magnetic microspheres coated with anti-acinar cell monoclonal antibodies. *Transplantation* 49(2): 404-7, 1990
34. Soon-Shiong P, Lu ZN, Grewal 1, Lanza RP, Clark W: An in vitro method of assessing the immunoprotective properties of microcapsule membranes using pancreatic and tumor cell targets. *Transplant Proc* 22(2): 754-5, 1990
35. Zheng T, Lu ZN, Chang YH, Merideth N, Lanza, RP, Soon-Shiong P: PGE<sub>2</sub> elevation occurs in the urine in both bladder and duodenally-drained pancreas allograft rejection. *Transplant Proc* 22(2):732-3, 1990
36. Zheng T, Koo A, Lu ZN, Levin S, Lanza RP, Soon-Shiong P: Urinary insulin as a marker of rejection in the bladder-drained pancreas allograft. *Transplant Proc* 22(2):667-8, 1990
37. Soon-Shiong P, Fujioka T, Terasaki P, Heintz R, Lanza RP: Islet purification by a novel immunomicrosphere cell depletion technique. *Transplant Proc* 22(2): 780-1, 1990
38. Soon-Shiong P, Lanza RP: The current status of pancreas and islet transplantation. *Postgrad Med* 87(8):133-4, 139-40, 1990

39. Soon-Shiong P, Terasaki P, Lanza RP: Immunocytochemical identification of monoclonal antibodies with binding activity to acinar cells but not islets. *Pancreas* 6(3): 318-23, 1991
40. Zheng T, Lanza RP, Soon-Shiong P: Prolonged pancreas preservation using a simplified UW solution containing polyethylene glycol (Cardiosol). *Transplantation* 51(1): 63-6, 1991
41. Soon-Shiong P, Lanza RP, Mendez R: Renal and pancreas transplantation in diabetic chronic uremic patients. In: 1991 International Yearbook of Nephrology. Andreucci VE, Fine LG (Eds). Kluwer Academic Publishers, Boston, 259-274, 1991
42. Zheng T, Schang T, Soon-Shiong P, Merideth N, Lanza R, Sutherland D: Pancreas function index: an early monitor of allograft rejection. *J Surg Res* 50: 24-9, 1991
43. Lanza RP, Soon-Shiong P: Xenotransplantation of encapsulated cells. In: Xenotransplantation: The transplantation of organs between species. Cooper DKE et al (Eds). Springer-Verlag, Heidelberg, 1991
44. Soon-Shiong P, Otterlie M, Skjak-Braek G, Smidsrod O, Heintz R, Lanza RP, Espevik T: An immunological basis for the fibrotic reaction to implanted microcapsules. *Transplant Proc* 23(1 Pt 1):758-9, 1991
45. Yao Z, Heintz R, Yao Q, Sandford P, Soon-Shiong P. Human C-peptide response in xenotransplanted diabetic Lewis rats. *Transplant Proc* 24(6): 2948-9, 1992
46. Otterlei, Ostgaard K, Skjak-Braek G, Smidsrod O, Soon-Shiong P, Espevik T: Induction of cytokine production from human monocytes stimulated with alginate. *J Immunother* 10: 286-91, 1991
47. Soon-Shiong P, et al. An immunologic basis for the fibrotic reaction to implanted microcapsules. *Transplant Proc* 23:758-759, 1991
48. Zheng T, Zhaonian L, Chang YH, Merideth N, Lanza R, Soon-Shiong P: Early markers of pancreas transplant rejection. *Am Surg* 58(10): 630-3, 1992
49. Soon-Shiong P: Recent advances in alginate-based microcapsules resulting in successful reversal of diabetes in the large animal model. In: *Pancreatic Islet Cell Transplantation*. Ricordi C (Ed). R.G. Landes, Austin, Chapter 19, 1992
50. Soon-Shiong P, Feldman E, Nelson R, Komtebedde J, Smidsrod O, Skjak-Braek G, Espevik T, Heintz R, Lee M: Successful reversal of spontaneous diabetes in dogs by intraperitoneal microencapsulated islets. *Transplantation* 54: 769-74, 1992

51. Soon-Shiong P: Glucose-insulin kinetics of the extravascular bioartificial pancreas: A study using microencapsulated rat islets. *ASAIO J* 38: 851-4, 1992
52. Soon-Shiong P, Feldman E, Nelson R, Heintz R, Merideth N, Sandford P, Zheng T, Komtebedde J: Long-term reversal of diabetes in the large animal model by encapsulated islet transplantation. *Transplant Proc* 24(6): 2946-27, 1992
53. Soon-Shiong P, Feldman E, Nelson R, Heintz R, Yao Q, Yao Z, Zheng T, Merideth N, Skjak-Braek G, Espevik T, Smidsrod O, Sandford P: Long-term reversal of diabetes by injection of immunoprotected islet cells. *Proc Natl Acad Sci* 90(12): 5843-7, 1993
54. Soon-Shiong P, Heintz R, Merideth N, Yao Qiang X, Yao Z, Zheng T, Murphy M, Moloney M, Schmehl M, Harris M, Mendez R, Sandford P: Insulin independence in a Type I diabetic patient after encapsulated islet transplantation. *Lancet* 343(8903): 950-1, 1994
55. Parker L, Lifrak E, Gelfand R, Shively J, Lee T, Kaplan B, Walker P, Calaycay J, Florsheim W, Mason I, Soon-Shiong P: Isolation, purification, synthesis and binding of human adrenal gland cortical androgen stimulating hormone: *Endocrine Journal* 1:441-445, 1993
56. Soon-Shiong, P. Encapsulated islet transplantation: Pathway to human clinical trials. *Pancreatic Islet Transplantation III* 81-92, 1994
57. Soon-Shiong P, Reversing Diabetes, *R&D Directions* 12-16, December 1995
58. Soon-Shiong P, Sandford P: Encapsulated islet cell therapy for the treatment of diabetes: intraperitoneal injection of islets. *Surgical Technology International* IV:93-95, 1995
59. Soon-Shiong P: Encapsulated islet cell therapy for the treatment of diabetes: Intraperitoneal injection of islets. *J Control Release*, 39(2-3):399-409, 1996
60. Thu B, Bruheim P, Espevik T, Smidsrod O, Soon-Shiong P, Skjak-Braek G: Alginate polycation microcapsules, I. Interaction between alginate and Polycation. *Biomaterials* 17(10): 1031-40, 1996
61. Thu B, Bruheim P, Espevik T, Smidsrod O, Soon-Shiong P, Skjak-Braek G: Alginate polycation microcapsules, II. Some functional properties. *Biomaterials* 17(11): 1069-79, 1996
62. Desai NP, Sojomihardjo A, Yao Z, Ron N, Soon-Shiong P: Interpenetrating polymer networks of alginate and polyethylene glycol for encapsulation of islets of Langerhans: *J Microencapsul* 17(6): 677-90, 2000

63. Soon-Shiong P: Treatment of type I diabetes using encapsulated islets. *Adv Drug Deliv Rev* 35(2-3): 259-270, 1999
64. Ci SX, Huynh TH, Louie LW, Yang A, Beals BJ, Ron N, Tsang WG, Soon-Shiong P, Desai NP: Molecular mass distribution of sodium alginate by high-performance size-exclusion chromatography: *J Chromatogr A* 864(2): 199-210, 1999
65. Desai, N. P., A. Sojomihardjo, Z. Yao, N. Ron and P. Soon-Shiong: Interpenetrating polymer networks of alginate and polyethylene glycol for encapsulation of islets of Langerhans. *J Microencapsul* 17(6): 677-90. 2000

### Abstracts

103. Soon-Shiong P, Debas HT, Brown JC: Cholinergic inhibition of gastric inhibitory polypeptide (GIP) action. *Gastroenterology* 76:1 153, 1979
104. Soon-Shiong P, Debas HT: Fundic inhibition of acid secretion and gastrin release. *Gastroenterology* 76:1253, 1979
105. Soon-Shiong P, Debas HT: Non-reversibility of fundusectomy-induced hypersecretion of acid by VIP and somatostatin. *Gastroenterology* 78:1257, 1980
106. Soon-Shiong P, Seal AM, Debas HT, Walsh JH: Colonic inhibition of gastric secretion in man. *Gastroenterology* 78:1367, 1980
107. Soon-Shiong P, Debas HT: Definition of vagal pathways mediating inhibition and stimulation of gastrin release in the dog. *Gastroenterology* 78:1266, 1980
108. Debas HT, Soon-Shiong P, Brown JC: Prevention by bethanechol of inhibition of gastric acid secretion by gastric inhibitory polypeptide (GIP). *Reg Peptides Suppl* 1:23, 1980
109. Soon-Shiong P, Debas HT: Non-somatostatin, non-VIP fundic inhibition of acid secretion and gastrin release. *Reg Peptides Suppl* 1:23, 1980
110. Soon-Shiong P, Bock LA, Debas HT: The role of hypergastrinemia in post fundusectomy acid hypersecretion. *Gastroenterology* 80:1290, 1981
111. Soon-Shiong P, Cox K, Iwashii-Hosoda C, Rosenquist G, Leung R: Increased serum-induced gallbladder bioactivity in cholelithiasis due to non-CCK substance. *Clin Res* 31:106A, 1983

112. Soon-Shiong P, Cox K, Iwashi-Hosoda C, Rosenquist G, Leung R: Increased serum-induced gallbladder bioactivity in cholelithiasis due to non-CCK substance. *Gastroenterology* 84:1317, 1983
113. Debas HT, Garcia R, Soon-Shiong P: Epidermal growth factor (EGF): Interactions with CCK and secretin on exocrine pancreatic secretion. *Gastroenterology* 86:1058, 1984
114. Strah K, Soon-Shiong P, Cox K, Rosenquist G, Reeve J, Walsh JH, Debas HT: Non-CCK stimulant of gallbladder contraction in human serum: Chromatographic, immunologic and biological comparisons to CCK. *Gastroenterology* 86:1267, 1984
115. Soon-Shiong P, Cox K, Rosenquist G, Iwashi-Hosida C: Increased serum concentrations of a noncholecystokinin stimulant of gallbladder contraction in patients with gallstone disease. *Dig Dis Sci* 29:82S, 1984
116. Strah K, Soon-Shiong P, Cox K, Walsh JH, Reeve J: Preliminary purification of a non-CCK stimulant of gallbladder contraction from porcine fundus. *Dig Dis Sci* 29:83S, 1984
117. Debas HT, Garcia R, Soon-Shiong P: Epidermal growth factor (EGF): In vivo interactions with CCK and secretin on exocrine pancreatic secretion. *Dig Dis Sci* 29:21S, 1984
118. Grewal I, Klandorf H, Soon-Shiong P: Role of NK cell activity in the pathogenesis of prediabetic insulinitis in NOD mice. *Diabetes* 37:208A, 1988
119. Degruccio AL, Klandorf H, Soon-Shiong P: Dimethylsulfoxide (DMSO) induces insulin release from perfused human islets. *Diabetes* 37:211A, 1988
120. Zheng TL, Lu ZN, Chang YH, Merideth N, Soon-Shiong P: Urinary PGE2 elevation occurs in pancreas allograft rejection, independent of the method of pancreatic duct drainage. *Diabetes* 38:246A, 1989
121. Zheng TL, Lu ZN, Levin S, Soon-Shiong P: Elevation of urine insulin in pancreas allograft rejection. *Diabetes* 38:248A, 1989
122. Lanza RP, Heintz R, Merideth N, Yao Z, Yao Q, Zavitz D, Chen C, Soon-Shiong P: Large-scale canine and human islet isolation using a physiological islet purification solution. *Diabetes* 39(1):309A, 1990
123. Soon-Shiong P, Heintz R, Yao Z, Yao Q, Lanza RP: Glucose-insulin kinetics of the extravascular bioartificial pancreas. *Diabetes* 39(1):311 A, 1990
124. Sawhney A, Soon-Shiong P, Hubbell J: Biocompatible microcapsules for in vivo transplantation of animal tissue. *Trans Soc for Biomaterials* 14, 1991

125. Soon-Shiong P, Heintz R, Merideth N, Feldman E, Nelson R, Skjak-Braek G, Smidsrod O, Espevik T, Otterlei M: Successful reversal of Type I diabetes by a bioartificial pancreas. *Diabetes* 40(1):295A, 1991
126. Skjak-Braek G, Thu B, Bruheim P, Soon-Shiong P, Sandford P, Heintz P, Espevik T, Smidsrod O: Structure-Function correlation of alginate-polycation capsules relevant to their use as a bioartificial pancreas. *Cell Transplantation* 1(2/3): 172, 1992
127. Soon-Shiong P, Feldman E, Nelson R, Heintz R, Merideth N, Sandford P, Lee M, Zheng T, Komtebedde J: Successful retransplantation of microencapsulated islets in spontaneous diabetic dogs: Long-term follow-up. *Cell Transplant* 1(2/3): 173, 1992
128. Yao Z, Heintz R, Yao Q, Sandford P, Soon-Shiong P: Human C-Peptide response in xenotransplanted diabetic Lewis rats. *Cell Transplant* 1(2/3): 175, 1992
129. Varsanyi-Nagy M, Zheng T, Merideth N, Nagrani S, Moloney M, Vaghefi F, Butze C, Lane B, Oh P, Yang S, Woodward T, Schmehl M, Sandford P, Soon-Shiong P: Long term function of porcine islets in vivo and in vitro. EASD, Islet Study Group, Hanover, Germany, 9/6-8 (22), 1996
130. Sandford P, Soon-Shiong P, Spaulding G: Alginate encapsulation of insulin producing cells: Intraperitoneal injection of islets for treatment of diabetes. American Chemical Society, 213th National Meeting, 4/13/97, San Francisco, California, USA
131. Desai NP, Tao C, Magdassi SM, Ci S, Yang A, Louie L, Valente G, Yao Z, Zheng T, Sandford P, Spaulding G, Soon-Shiong P: Protein-stabilized nanoparticles as drug delivery vehicles. 23rd Annual Meeting of the Society for Biomaterials, 4/30-5/4, 1997, New Orleans, Louisiana, USA
132. Ibrahim NK, Ellerhorst JA, Theriault RL, Rivera E, Esmali B, Legha SS, Ring SE, Soon-Shiong P, Benjamin RS, Hortobagyi GN: Phase I study of cremophor-free, protein-stabilized , nanoparticle formulation of paclitaxel (ABI-007) in solid tumors. Thirty-sixth Annual Meeting, American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA, USA.
133. Damascelli Sr. B, Soon-Shiong P, Desai N, Di Tolla G, Frigerio L, Garbagnati F, Lanocita R, Marchianò A, Patelli G, Spreafico C, Bidoli P, Cantù G: A novel intra-arterial chemotherapeutic approach to squamous cell cancer of head and neck and anal canal using high dose cremaphore-free paclitaxel/albumin nanoparticles (ABI-007). Thirty-sixth Annual Meeting, American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA, USA.
134. Desai NP, Louie L Ron S, Magdassi S, Soon-Shiong P: Protein-based nanoparticles for drug delivery of paclitaxel. Sixth World Biomaterials Congress, May 15-20, 2000, Kamuela, Hawaii, USA.

135. Desai NP, Yao Z., Soon-Shiong P: Evidence of Enhanced In Vivo Efficacy at Maximum Tolerated Dose (MTD) of Nanoparticle Paclitaxel (ABI-007) versus Taxol in 5 Human Tumor Xenografts of Varying Sensitivity to Paclitaxel. May 18-21, 2002, Orlando, Florida, USA.
126. Ibrahim NK, Samuels B., Page R., Guthrie T., Ramakrishnan G., Doval D., Patel K., Rao S., Nair M., Digumarti R., Hortabagyi GN.: Nanoparticle Paclitaxel (ABI-007) in Metastatic Breast Cancer (MBC): Efficacy and Evidence of Dose-dependent Activity in Two Multicenter Phase II Studies. May 18-21, 2002, Orlando, Florida, USA.
127. Campbell KJ., Hersh EM., Stopeck AT., Glennie K., Simpson GA., Taylor C., Von Hoff DD.: A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-hematologic Malignancies. May 18-21, 2002, Orlando, Florida, USA.
128. Ibrahim NK., Samuels B., Page R., Guthrie T. Jr., Doval D., Patel KM., Rao SC., Nair M., Digumarti R., Hortobayi GN.: Efficacy and Dose-Dependent Activity of ABI-007, a Cremophor®-Free Nanoparticle Paclitaxel, in First-Line Metastatic Breast Cancer: Integrated Results of Two Phase II Trials. December 11-14, 2002, San Antonio, Texas, USA.
129. Taylor C., Ibrahim NK., Page R., Guthrie T. Jr., Rao SC., Digumarti R., Desai N., Soon-Shiong P.: Preliminary Evidence of Antitumor Activity of ABI-007, a Cremophor®-Free Nanoparticle Paclitaxel, in Patients Previously Exposed to Taxanes. December 11-14, 2002, San Antonio, Texas, USA.
130. Desai N., Campbell K., Ellerhorst J., Ibrahim NK., Soon-Shiong P.: Preclinical and Clinical Pharmacokinetics and Safety of ABI-007-a Novel, Cremophor®-Free, Protein-Engineered Nanotransporter of Paclitaxel. December 11-14, 2002, San Antonio, Texas, USA.
131. Desai N., Yao Z., Trieu V., Soon-Shiong P., Dykes D., Noker P.: Evidence of a Novel Transporter Mechanism for a Cremophor®-Free, Protein-Engineered Paclitaxel (ABI-007) and Enhanced In Vivo Antitumor Activity in an MX-1 Human Breast Tumor Xenograft Model. December 11-14, 2002, San Antonio, Texas, USA.

